Draft Guidance for Industry on Suicidality: Prospective Assessment of Occurrence in Clinical Trials; Availability, 54889-54890 [2010-22404]
Download as PDF
Federal Register / Vol. 75, No. 174 / Thursday, September 9, 2010 / Notices
the docket number found in brackets in
the heading of this document.
Comments and petitions that have not
been made publicly available on
regulations.gov may be viewed in the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
Dated: August 13, 2010.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. 2010–22394 Filed 9–8–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[ATSDR–265]
Development of Set 24 Toxicological
Profiles
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (DHHS).
ACTION: Notice.
AGENCY:
Profiles will be available to the
public on or about October 17, 2010.
SUMMARY: The Agency for Toxic
Substances and Disease Registry
(ATSDR) of the Department of Health
and Human Services is developing Set
24 Toxicological Profiles. Set 24
Toxicological Profiles consists of one
new draft and one updated draft.
Electronic access to these documents
will be available at the ATSDR Web site:
https://www.atsdr.cdc.gov/toxpro2.html.
DATES:
Set 24 Toxicological Profiles
The following toxicological profiles
are now being developed:
Toxicological profile
Toxaphene ............................
Trichlorobenzene*
1,2,3–Trichlorobenzene
1,2,4–Trichlorobenzene
1,3,5–Trichlorobenzene
Trichlorobenzene ....
FOR FURTHER INFORMATION CONTACT:
Commander Jessilynn B. Taylor,
Division of Toxicology and
Environmental Medicine, Agency for
CAS number
Toxic Substances and Disease Registry,
8001–35–2 1600 Clifton Road, NE., Mail Stop F–62,
Atlanta, GA 30333; telephone (770)
87–61–6 488–3313; e-mail: JBTaylor@cdc.gov.
120–82–1
108–70–3
12002–48–1
* Denotes new profile.
The
Superfund Amendments and
Reauthorization Act of 1986 (42 U.S.C.
9601 et seq.) amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA) (42 U.S.C. 9601
et seq.) by establishing certain
requirements for ATSDR and the U.S.
Environmental Protection Agency (EPA)
mstockstill on DSKH9S0YB1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
17:24 Sep 08, 2010
with regard to hazardous substances
that are most commonly found at
facilities on the CERCLA National
Priorities List. Among these statutory
requirements is a mandate for the
Administrator of ATSDR to prepare
toxicological profiles for each substance
included on the Priority List of
Hazardous Substances (https://
www.atsdr.cdc.gov/cercla/07list.html).
This list names 275 hazardous
substances that pose the most
significant potential threat to human
health as determined by ATSDR and
EPA. The availability of the revised list
of the 275 priority substances was
announced in the Federal Register on
March 6, 2008 (73 FR 12178). For prior
versions of the list of substances, see
Federal Register notices dated April 17,
1987 (52 FR 12866); October 20, 1988
(53 FR 41280); October 26, 1989 (54 FR
43619); October 17, 1990 (55 FR 42067);
October 17, 1991 (56 FR 52166); October
28, 1992 (57 FR 48801); February 28,
1994 (59 FR 9486); April 29, 1996 (61
FR 18744; November 17, 1997 (62 FR
61332); October 21, 1999 (64 FR 56792);
October 25, 2001 (66 FR 54014);
November 7, 2003 (68 FR 63098); and
December 7, 2005 (70FR 70284).
Notice of the availability of drafts of
one updated and one new toxicological
profile for public review and comment
will be published in the Federal
Register on or about October 17, 2010,
with notice of a 90-day public comment
period for each profile, starting from the
actual release date. Following the close
of the comment period, chemicalspecific comments will be addressed,
and where appropriate, revisions will be
incorporated into each profile.
Jkt 220001
Dated: September 3, 2010.
Ken Rose,
Associate Director, Office of Policy, Planning
and Evaluation, National Center for
Environmental Health/Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2010–22439 Filed 9–8–10; 8:45 am]
BILLING CODE 4163–70–P
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
54889
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0451]
Draft Guidance for Industry on
Suicidality: Prospective Assessment of
Occurrence in Clinical Trials;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Suicidality:
Prospective Assessment of Occurrence
in Clinical Trials.’’ The purpose of this
guidance is to assist sponsors in
prospectively assessing the occurrence
of treatment-emergent suicidality in
clinical trials of drug and biological
products. Specifically, this guidance
addresses FDA’s current thinking
regarding the importance of suicidality
assessment in psychiatric and
nonpsychiatric drug trials and the
general principles for how best to
accomplish this assessment during drug
development.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by November 8,
2010.
SUMMARY:
Submit written requests for
single copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Thomas Laughren, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 4114,
Silver Spring, MD 20993–0002, 301–
796–2260.
ADDRESSES:
E:\FR\FM\09SEN1.SGM
09SEN1
54890
Federal Register / Vol. 75, No. 174 / Thursday, September 9, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Suicidality: Prospective Assessment of
Occurrence in Clinical Trials.’’ The
purpose of this guidance is to assist
sponsors in prospectively assessing the
occurrence of treatment-emergent
suicidality in clinical trials of drug and
biological products. Specifically, this
guidance addresses FDA’s current
thinking regarding the importance of
suicidality assessment in psychiatric
and nonpsychiatric drug trials and the
general principles for how best to
accomplish this assessment during drug
development.
The principles discussed in this
guidance for the prospective assessment
of suicidality involve actively querying
patients about the occurrence of suicidal
thinking and behavior, rather than
relying on patients to report such
occurrences spontaneously, followed by
retrospective classification of events
into appropriate categories. This
guidance recommends a specific
suicidality assessment instrument that
can be used to conduct such prospective
assessments and offers guidance on the
use of alternative instruments. This
guidance does not address the complex
analytic issues involved in the analysis
of the suicidality data that will be
derived from prospective assessments of
suicidality; these issues will be
addressed in separate guidances.
Comments are welcome regarding the
recommended approach of carrying out
prospective suicidality assessments in
all clinical trials for all drugs that are
pharmacologically similar to
isotretinoin and other tretinoins, beta
blockers (especially those entering the
brain), reserpine, drugs for smoking
cessation, and drugs for weight loss for
which possible signals of risk for
suicidality have already been identified.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on the prospective assessment of
suicidality occurrence in clinical trials.
It does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
VerDate Mar<15>2010
17:24 Sep 08, 2010
Jkt 220001
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Dated: September 2, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–22404 Filed 9–8–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Neonatal Research
Network.
Date: October 5–6, 2010.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Legacy Hotel and Meeting Center,
1775 Rockville Pike, Rockville, MD 20852.
Contact Person: Rita Anand, PhD,
Scientific Review Officer, Division of
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Bethesda, MD 20892,
301–496–148, anandr@mail.nih.gov.
Frm 00045
Fmt 4703
Dated: September 2, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–22499 Filed 9–8–10; 8:45 am]
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
PO 00000
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentablematerial,
and personal information concerning
individuals associated with the grant
applications,the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Aging and
Distal Radius Fracture.
Date: October 7, 2010.
Time: 6 p.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Alicja L. Markowska, PhD,
DSC, Scientific Review Branch, National
Institute on Aging, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892, 301–496–
9666, markowsa@nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Aminergic
Function in Brain Aging and Alzheimer’s
Disease.
Date: October 19, 2010.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Alexander Parsadanian,
Ph.D., Scientific Review Officer, National
Institute on Aging, Gateway Building 2C/212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666,
PARSADANIANA@NIA.NIH.GOV.
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 75, Number 174 (Thursday, September 9, 2010)]
[Notices]
[Pages 54889-54890]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-22404]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-D-0451]
Draft Guidance for Industry on Suicidality: Prospective
Assessment of Occurrence in Clinical Trials; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Suicidality:
Prospective Assessment of Occurrence in Clinical Trials.'' The purpose
of this guidance is to assist sponsors in prospectively assessing the
occurrence of treatment-emergent suicidality in clinical trials of drug
and biological products. Specifically, this guidance addresses FDA's
current thinking regarding the importance of suicidality assessment in
psychiatric and nonpsychiatric drug trials and the general principles
for how best to accomplish this assessment during drug development.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by November 8, 2010.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the draft guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Thomas Laughren, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 4114, Silver Spring, MD 20993-0002, 301-
796-2260.
[[Page 54890]]
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Suicidality: Prospective Assessment of Occurrence in
Clinical Trials.'' The purpose of this guidance is to assist sponsors
in prospectively assessing the occurrence of treatment-emergent
suicidality in clinical trials of drug and biological products.
Specifically, this guidance addresses FDA's current thinking regarding
the importance of suicidality assessment in psychiatric and
nonpsychiatric drug trials and the general principles for how best to
accomplish this assessment during drug development.
The principles discussed in this guidance for the prospective
assessment of suicidality involve actively querying patients about the
occurrence of suicidal thinking and behavior, rather than relying on
patients to report such occurrences spontaneously, followed by
retrospective classification of events into appropriate categories.
This guidance recommends a specific suicidality assessment instrument
that can be used to conduct such prospective assessments and offers
guidance on the use of alternative instruments. This guidance does not
address the complex analytic issues involved in the analysis of the
suicidality data that will be derived from prospective assessments of
suicidality; these issues will be addressed in separate guidances.
Comments are welcome regarding the recommended approach of carrying
out prospective suicidality assessments in all clinical trials for all
drugs that are pharmacologically similar to isotretinoin and other
tretinoins, beta blockers (especially those entering the brain),
reserpine, drugs for smoking cessation, and drugs for weight loss for
which possible signals of risk for suicidality have already been
identified.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the agency's current thinking on the
prospective assessment of suicidality occurrence in clinical trials. It
does not create or confer any rights for or on any person and does not
operate to bind FDA or the public. An alternative approach may be used
if such approach satisfies the requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or https://www.regulations.gov.
Dated: September 2, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-22404 Filed 9-8-10; 8:45 am]
BILLING CODE 4160-01-P